New data from TauRx Therapeutics' Phase III LUCIDITY trial demonstrates LMTX reduced cognitive decline by 82% compared to matched placebo at 18 months in patients with mild cognitive impairment and Alzheimer's disease.
TauRx Pharmaceuticals has raised $119 million through warrant exercises from existing investors, bolstering its resources for upcoming regulatory submissions of HMTM, a tau-targeting Alzheimer's treatment.
Hydromethylthionine mesylate (HMTM), a daily oral medication developed by TauRx, is under review by UK regulators for potential NHS use in treating Alzheimer's disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.